- Hospitex, a world leader in Thin Layer Cytology and Cancer
Diagnostics, providing a competitive solution based on a patented
and cutting-edge technology, the Nephelometric Smart Technology
(NST)
- A key milestone in the deployment of Ikonisys’ growth
strategy, with strong technological and commercial synergies to
drive continuous improvement in revenue and profitability by:
- Combining two proprietary technologies, expanding Ikonisys’
existing expertise upstream in the value chain adding Hospitex’s
superior solution for slide preparation;
- Building on the complementary organization of Hospitex to
become a player of excellence in cancer diagnostics with a
comprehensive vertical solution;
- Strengthening the geographical reach, leveraging on Ikonisys’
commercial network in the USA and Hospitex’s established network in
Europe.
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO) (the
“Issuer”), a company specializing in the early and accurate
detection of cancer through a unique fully automated solution for
medical analysis laboratories, today announces its entry into an
agreement (the “Agreement”) in order to acquire 100% of
Hospitex International (“Hospitex”), an Italian-based world
leader in Thin Layer Cytology and Cancer Diagnostics (the
“Transaction”).
Hospitex is a technological world leader for laboratory
instrumentations in cytology and has developed a unique patented
platform for slide preparation called Nephelometric Smart
Technology (NST). Thanks to its proprietary CYTOfast system,
Hospitex provides the most advanced solution for very accurate
standardized single-layer liquid-based cytology (LBC) slides. This
cutting-edge technology enables Hospitex to produce high-quality
thin layer diagnostic slides for any organ targeted. These superior
quality slides will ensure best-in-class images when analyzed by
the Ikoniscope fully automated solution.
In addition to its core business, Hospitex already operates in
three other complementary business units:
- Hospitex Labs: provider of turn-key laboratories for cancer
diagnostics;
- Hospitex Digital: integrator of ICT systems for healthcare
laboratories, through AI development and Big Data in oncology;
and
- Urine24: manufacturer and supplier of a BtoC solution, the
first urinary tract cancer screening test sold in pharmacies.
In 2022, Hospitex generated €1.8 million revenues with an EBITDA
margin of 21%. Hospitex has 23 employees and relies on an extensive
sales network, tapping into agents and distributors to promote its
solutions across Europe.
With this strategic acquisition, Ikonisys will integrate
Hospitex's extensive expertise in slide preparation upstream in the
value chain, offering an integrated solution to pathology
laboratories and completing its existing product line for automated
slide analysis. This will result in an additional increase in
efficiency and effectiveness of the cancer diagnostic process. In
addition, the Issuer will benefit from business synergies and cost
optimizations derived by a complementary, integrated, and vertical
offer to the same customers.
Together, the companies will offer premium efficient cancer
diagnostic solutions on a global scale.
Mario Crovetto, CEO of Ikonisys, stated: "We are pleased
to announce this strategic acquisition. Hospitex has proven its
ability to develop a cutting-edge patented technology, which is
truly complementary to Ikonisys’ solutions. By combining our
expertise, we aim to enhance both final diagnosis and laboratory
processes, through advanced automation and digitalization of the
entire value chain of pathology labs, from slide preparation to
analysis. Thanks to our comprehensive vertical solution, we are a
player of excellence in cancer diagnostics and look forward to
become a world leader in this field."
Francesco Trisolini, CEO of Hospitex International,
added: “By combining our technology with Ikonisys, we are
exploiting a great opportunity to expand our technical, commercial
and geographical reach. The opportunity to combine technologies for
first- and second-level diagnosis opens the way to important
breakthroughs, such as liquid biopsy, also on urinary matrix.
Together, we will further strengthen our impact on the cancer
diagnostics field by providing a comprehensive fully integrated
solution to the pathology laboratories. Finally, we can deploy
Ikonisys technology in our mass screening solutions, to reach a
potential unlimited customer basis.”
Consideration
Under the terms of the Agreement, Ikonisys will complete the
acquisition of 100% of Hospitex International for a total
consideration of €4.5 million, paid through the issuance of 2
million new Ikonisys shares at a price of €2.25 per share,
corresponding to a premium of 61% on the volume-weighted average
price of the shares observed on Euronext Growth Paris over the 5
trading days preceding this announcement. The Transaction, which is
subject to customary conditions precedent, is expected to be
completed by February 2024.
In addition, if certain revenue targets are reached by Hospitex
by December 31, 2024, an additional €1.125 million will be paid by
Ikonisys in June 2025 through the issuance of additional 0.5
million new Ikonisys shares at a price of €2.25 (together with the
initial 2 million new Ikonisys shares, the “Consideration
Shares”).
The issuance of the Consideration Shares shall occur with
cancellation of the shareholders’ preferential subscription
right.
The total value of the transaction has been validated by an
independent expert.
The Consideration Shares which may be issued shall be admitted
to trading on Euronext Growth Paris, on the same line as existing
Ikonisys shares (ISIN: FR00140048X2 – Ticker: ALIKO).
The issuance of the Consideration Shares will not require the
approval of a prospectus by the AMF.
Lock-up commitment of the sellers
The sellers agreed to grant a lock-up commitment on all
Consideration Shares that they may receive in consideration for the
Transaction, until June 30, 2025 (the “Lock-Up Commitment”),
except in customary circumstances or with the prior approval of the
Issuer.
Right to a board seat
In the framework of the Transaction, the appointment of Mr.
Francesco Trisolini, current chief executive officer of Hospitex,
shall be submitted to the vote of the next shareholders’ meeting of
the Issuer for a duration of three (3) years.
Theoretical impact of the issuance of the Consideration
Shares
Based on the 9,784,757 shares outstanding and the equity as at
December 31, 2022 (i.e., €17,671,473), the theoretical impact on
equity per share would be:
Theoretical impact on equity per
share
Non-diluted basis
Diluted basis
Before the closing
€1.81
€1.73
After the issuance of 2,000,000 new
shares
€1.88
€1.82
After the issuance of 500,000 new shares
due to the potential earn-out
€1.90
€1.83
Based on the 9,784,757 shares outstanding, the theoretical
impact on a shareholder holding a 1% stake in the Issuer’s share
capital prior to the Transaction would be:
Theoretical impact on a shareholder
holding a 1% stake in Ikonisys’ share capital prior to the
closing
Non-diluted basis
Diluted basis
Before the closing
1.00%
0.96%
After the issuance of 2,000,000 new
shares
0.83%
0.80%
After the issuance of 500,000 new shares
due to the potential earn-out
0.80%
0.77%
Main risks associated with the Issuer
The main risks associated with the Issuer are set out in the
2022 annual financial report for the financial year ended December
31, 2022, published on April 29, 2023, and in the half-year report
2023, published on October 31, 2023 and available on the website of
the Issuer (www.Ikonisys.com).
Main risks associated with the issuance of the Consideration
Shares
The main risks associated with the issuance of the Consideration
Shares are the following:
- risk of dilution of the Issuer’s shareholders: the Issuer’s
shareholders will suffer dilution upon issuance of the
Consideration Shares;
- risk relating to the evolution of the Ikonisys share price: the
expiry of the Lock-Up Commitment may create strong pressure
downward trend on Ikonisys’ share price, and the Issuer’s
shareholders may, upon such expiry, suffer a loss of their invested
capital due to a significant decrease in the value of Ikonisys’
shares;
- risk of availability and liquidity of the Issuer’s shares: the
sale on the market of the Consideration Shares upon the expiry of
the Lock-Up Commitment is likely to have significant consequences
on the availability and liquidity of Ikonisys’ shares.
Tentative schedule
- Completion of the Transaction: February 2024
- Issuance of 500,000 Ikonisys shares as payment of the earn-out
(as the case may be): June 2025
- Expiry of the Lock-Up Commitment: June 30, 2025
Allocation of the share capital before and after the issuance
of the Consideration Shares
The shareholding table below presents the allocation of the
share capital as of the day of this announcement:
Number of shares
% capital
Cambria Co-Invest. Fonds LP
5,268,989
53.85%
Cambria Equity Partners, LP
2,374,049
24.26%
MC Consulting S.r.l.*
351,464
3.59%
Free-float
1,790,255
18.30%
9,784,757
100.00%
* Holding of Mr Mario Crovetto, CEO of
Ikonisys.
The shareholding table below presents the theoretical allocation
of the share capital following the issuance of 2 million Ikonisys
shares:
Number of shares
% capital
Cambria Co-Invest. Fonds LP
5,268,989
44.71%
Cambria Equity Partners, LP
2,374,049
20.15%
MC Consulting S.r.l.*
351,464
2.98%
Free float
1,790,255
15.19%
Sellers (previous Hospitex
shareholders)
2,000,000
16.97%
11,784,757
100.00%
* Holding of Mr Mario Crovetto, CEO of
Ikonisys.
The shareholding table below presents the theoretical allocation
of the share capital following the issuance of the Consideration
Shares:
Number of shares
% capital
Cambria Co-Invest. Fonds LP
5,268,989
42.89%
Cambria Equity Partners, LP
2,374,049
19.33%
MC Consulting S.r.l.*
351,464
2.86%
Free-float
1,790,255
14.57%
Sellers (previous Hospitex
shareholders)
2,500,000
20.35%
12,284,757
100.00%
* Holding of Mr Mario Crovetto, CEO of
Ikonisys.
About Hospitex International
Hospitex International is the world leading company for cytology
standardized monolayer preparations. With CYTOfast it has
re-invented the cytological diagnostics. Hospitex offers a full
range of integrated solutions aimed at streamlining diagnostic
processes in cytology. The global shortage of expertise in
pathology requires tools and technologies that enable diagnostic
safety, efficiency and capacity building. In this area, Hospitex is
recognized as the precision diagnostics player in cytology.
For more information: https://www.hospitex.com/en/
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231129839137/en/
Hospitex International Marco Testini Investor Relations
marketing@hospitex.com
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024